IMI News Alert Intermolecular Inc (IMI) 1.70 02/14/2015 01:0

New Post Public Reply Private Reply Replies (0) Message Board

Feb 14, 2015 at 2:06 AM

Intermolecular Inc (IMI) 1.70 $IMI

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 11:45AM CST

CYTK: 7.78 (+1.29), MNOV: 3.62 (-0.56), MX: 7.52 (-7.50), SIEB: 1.71 (-0.24), QKLS: 2.10 (-0.24), YUMA: 1.88 (+0.67), CYBR: 52.52 (+6.83), KN: 18.59 (-3.05), COLM: 51.50 (+7.91), BIOC: 1.41 (+0.22), NBG: 1.61 (+0.18), CECO: 5.34 (-0.92), GENE: 8.04 (+1.90), SGNL: 3.91 (+2.15), IMI: 1.70 (-0.20), RCKY: 18.43 (+4.33), WAC: 20.29 (+2.57), FNJN: 2.77 (-0.36), ZNGA: 2.24 (-0.42), PRAN: 1.09 (-0.55)

Intermolecular Inc (IMI) CEO Bruce McWilliams on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 12, 7:42PM CST

IMI: 1.70 (-0.20)

Intermolecular reports 4Q loss
Automated Insights - Thu Feb 12, 7:01PM CST
SAN JOSE, Calif. (AP) _ Intermolecular Inc. (IMI) on Thursday reported a loss of $6.1 million in its fourth quarter.
IMI: 1.70 (-0.20)

Intermolecular EPS in-line, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 3:43PM CST

IMI: 1.70 (-0.20)

Intermolecular Announces Full Year and Fourth Quarter 2014 Results
Business Wire - Thu Feb 12, 3:15PM CST
Intermolecular, Inc. (NASDAQ:IMI)-accelerating research and development (R&D) for semiconductor and clean energy industries-today announced results for its full year and fourth quarter ended December 31, 2014.
IMI: 1.70 (-0.20)

Nasdaq stocks posting largest volume increases
AP - Tue Feb 10, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
HNNA: 24.40 (+0.40), OFED: 20.41 (+0.16), DLHC: 2.21 (-0.06), BELFB: 23.44 (+0.60), BELFA: 19.90 (-0.40), BIOC: 1.41 (+0.22), NWFL: 30.00 (+0.25), ATOS: 1.67 (+0.11), SPDC: 1.18 (+0.05), FSC: 7.23 (+0.12), OVBC: 24.00 (unch), QTWW: 2.96 (-0.04), ANTH: 3.84 (+0.06), IMI: 1.70 (-0.20), FBMS: 14.69 (+0.31), EXA: 10.46 (+0.09), FNJN: 2.77 (-0.36)

Intermolecular to Report Fourth Quarter and FY2014 Financial Results on February 12, 2015
Business Wire - Fri Jan 23, 3:30PM CST
Intermolecular, Inc. (NASDAQ: IMI)--accelerating research and development for semiconductor and clean energy industries--today announced it will release financial results for the fiscal fourth quarter ended December 31, 2014 and fiscal year 2014 after the U.S. financial markets close on Thursday, February 12, 2015. In conjunction with the release, Intermolecular will host a conference call and simultaneous audio-only webcast at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time with Bruce McWilliams, president and chief executive officer, and Rick Neely, senior vice president and chief financial officer, for Intermolecular.
IMI: 1.70 (-0.20)

InsiderInsights.com Daily Round Up 11/5/14: ELGX, NS, BIOL, NHF
InsiderInsights - at Seeking Alpha - Thu Nov 06, 3:19AM CST

VR: 42.10 (+0.07), JBHT: 82.88 (+1.09), FCX: 20.29 (+0.82), BBY: 39.11 (-0.08), NS: 61.94 (-0.06), LL: 63.69 (+0.89), ELGX: 14.51 (+0.21), ENFC: 15.40 (+0.12), RCL: 75.56 (-1.19), LMCA: 37.97 (+0.06), SPW: 87.37 (-2.81), OPK: 13.80 (-0.28), BIOL: 2.22 (+0.22), IMI: 1.70 (-0.20), NHF: 11.69 (+0.08), SIX: 45.11 (-0.05), TWTR: 48.50 (+0.55), SCHW: 29.13 (-0.83)

Quanta Raises £27 Million to Prepare its Advanced Haemodialysis System SC+ for Launch
PR Newswire - Mon Nov 03, 1:00AM CST
~ Funding Round Led by ALIAD the Venture Vehicle of Air Liquide ~
IMI: 1.70 (-0.20), AI: 25.03 (-0.03)

Intermolecular's (IMI) CEO Bruce McWilliams on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Oct 31, 11:22AM CDT

IMI: 1.70 (-0.20)

Intermolecular beats by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 7:18AM CDT

IMI: 1.70 (-0.20)

Intermolecular posts 3Q loss
Automated Insights - Fri Oct 31, 7:18AM CDT
SAN JOSE, Calif. (AP) _ Intermolecular Inc. (IMI) on Friday reported a loss of $5 million in its third quarter.
IMI: 1.70 (-0.20)

Intermolecular Announces Third Quarter 2014 Financial Results
GlobeNewswire - Fri Oct 31, 7:11AM CDT
Intermolecular, Inc. (Nasdaq:IMI) -- accelerating research and development for semiconductor and clean energy industries -- today announced results for its third quarter ended September 30, 2014.
IMI: 1.70 (-0.20)

Intermolecular to Report Third Quarter 2014 Financial Results on October 31, 2014
GlobeNewswire - Wed Oct 15, 3:51PM CDT
Intermolecular, Inc. (Nasdaq:IMI)--accelerating research and development for semiconductor and clean energy industries--today announced it will release financial results for the fiscal third quarter ended September 30, 2014 on Friday, October 31, 2014. In conjunction with the release, Intermolecular will host a conference call and simultaneous audio-only webcast at 8:30 a.m. Eastern Time/5:30 a.m. Pacific Time with Bruce McWilliams, president and chief executive officer, and Rick Neely, senior vice president and chief financial officer, for Intermolecular.
IMI: 1.70 (-0.20)

Intermolecular Appoints Dr. Bruce McWilliams as President and Chief Executive Officer
GlobeNewswire - Mon Oct 13, 8:45AM CDT
Intermolecular, Inc. (Nasdaq:IMI)--accelerating research and development for semiconductor and clean energy industries--today announced that Dr. Bruce McWilliams has been appointed president and chief executive officer. David Lazovsky has resigned as president and chief executive officer and from the Board of Directors to pursue other interests.
IMI: 1.70 (-0.20)

Intermolecular Announces Second Quarter 2014 Financial Results
GlobeNewswire - Fri Aug 01, 7:41AM CDT
Intermolecular, Inc. (Nasdaq:IMI)--accelerating research and development (R&D) for semiconductor and clean energy industries--today announced results for its second quarter ended June 30, 2014.
IMI: 1.70 (-0.20)

Intermolecular to Report Second Quarter 2014 Financial Results on August 1, 2014
GlobeNewswire - Fri Jul 11, 3:10PM CDT
Intermolecular, Inc. (Nasdaq:IMI) today announced it will release financial results for the fiscal second quarter ended June 30, 2014 on Friday, August 1, 2014. In conjunction with the release, Intermolecular will host a conference call and simultaneous audio-only webcast at 8:30 a.m. Eastern Time/5:30 a.m. Pacific Time with David Lazovsky, President and Chief Executive Officer, and Rick Neely, Senior Vice President and Chief Financial Officer, for Intermolecular.
IMI: 1.70 (-0.20)

Intermolecular, Inc. (IMI) Soars: Stock Adds 14% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 7:30AM CDT
Intermolecular, Inc. (IMI) was a big mover last session, as its shares rose over 14% on the day.
MXWL: 6.47 (+0.07), AUO: 5.45 (-0.14), IMI: 1.70 (-0.20)

Regulatory Disclosures, Awards, Performance Reviews, and Production Report Schedules - Analyst Notes on IMI, WPP, JD Sports, Antofagasta and CRH
PR Newswire Europe - Thu Jun 26, 12:01AM CDT
LONDON, June 25, 2014 /PRNewswire/ --
CRH: 28.02 (-0.09), IMI: 1.70 (-0.20), JD: 26.23 (-0.27), WPP: 9.80 (+0.10)

Intermolecular Announces New Chairman
GlobeNewswire - Wed Jun 18, 7:30AM CDT
Intermolecular, Inc. (Nasdaq:IMI)--accelerating research and development for semiconductor and clean energy industries--today announced that Dr. Bruce McWilliams has been appointed Chairman of the Board, taking over the chairman position from Tom Baruch. Mr. Baruch has served as chairman for almost eight years, and he will remain on the Intermolecular board as an active director.
IMI: 1.70 (-0.20)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

UEG's New Advisory Board: Elevating Patient Voices

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Lundbeck's Board Leadership Transitions into New Era

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Tomorrowland's Shanghai Return: An Electri-Lifesaver

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

ASTS Faces a Legal Countdown – Investors Take Note

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

AEVEX Faces 48-Hour Deadline for Investor Class Action

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Faith and Resilience in China: The Legacy of the Long March

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Antheia Secures $80M for Critical Medicine Onshoring

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...